New test could predict life-threatening side effects of cancer immunotherapy

Medical researchers in Japan have discovered a way to predict a potentially life-threatening side effect of cancer immunotherapy before it occurs.

Accord BioPharma’s HERCESSI gets FDA approval

HERCESSI is approved for treating HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. Credit: Lightspring/Shutterstock. Accord BioPharma, the speciality division

Read More »